Sign in
Taking people in United StatesNo phase

Copper supplements for adults with cirrhosis of the liver

Tests copper gluconate supplements against placebo in adults with cirrhosis.

Key facts

Who runs it
University of Washington
Where
Seattle, United StatesSee the site
Trial code
Registry title
Copper Supplementation in Cirrhosis
Status
Recruiting
People taking part
30 people, planned
Started
15 Mar 2026
Expected to end
Dec 2028
Type of study
Interventional, 2 groups
Treatments tested
  • Copper Gluconate
Record updated
13 March 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with cirrhosis (severe liver scarring) who have low copper in the blood, or normal copper with signs linked to low copper. It tests copper supplements against a placebo (dummy pill).

Age
18 years or older
Sex
All sexes
Disease stage
Confirmed cirrhosis. People with a MELD score (a liver disease severity score) above 25 cannot join.
Biomarker or test result
Blood copper below normal (80-155 ug/dL for women, 70-140 ug/dL for men). Or normal copper plus at least one sign linked to low copper: past infections, unexplained anemia, severe leukopenia (very low white blood cells), iron overload, unexplained nerve symptoms such as ataxia or myelopathy, or clotting problems with spontaneous bleeding.

Main reasons for not taking part

  • Wilson disease, primary biliary cholangitis or primary sclerosing cholangitis
  • Sudden severe liver failure (fulminant hepatic failure), or hepatic encephalopathy (brain problems from liver disease) more than grade 2
  • Kidney failure with creatinine clearance <25 ml/minute
  • Serious illness not related to the liver, such as heart, lung or kidney disease or cancer outside the liver
  • Current alcohol use, or pregnancy

The registry criteria, word for word

Show all 11 criteriaShow less

Who can take part

  • Adult patients age 18 or older with confirmed diagnosis of cirrhosis based on clinical history, exam, imaging, laboratory or histological criteria
  • Cirrhosis patients whose serum or plasma Cu are below the normal range (80-155 ug/dL for women and 70-140 ug/dL for men)
  • Cirrhosis patients whose serum or plasma Cu are in the normal range but exhibit at least one clinical feature that has been associated with Cu deficiency. These include history of infections, unexplained anemia, severe leukopenia, iron overload, unexplained neurological symptoms such as ataxia or myelopathy, coagulopathy with spontaneous bleeding; Patients must meet inclusion criteria 1 AND 2, or 1 AND 3 in order to be considered for the trial

Who cannot take part

  • Patients with Wilson disease, cholestatic liver diseases including primary biliary cholangitis and primary sclerosing cholangitis, all of which are associated with Cu overload
  • Patients with fulminant hepatic failure
  • Hepatic encephalopathy more than grade 2 (Hepatic Encephalopathy in Chronic Liver Disease, 2014)
  • Serious non-liver related medical illnesses such as cardiopulmonary and renal diseases and non-liver malignancies
  • Renal failure with a creatinine clearance <25 ml/minute
  • MELD score >25 to minimize subject dropout due to been too ill
  • Active alcohol use
  • Pregnancy

Where in United States

  • University of Washington Medical CenterSeattle, United StatesContact: Shukriyah Samoun, BSTaking people

About the trial

What the trial wants to find out

End stage liver disease or cirrhosis is a major cause of mortality in the United States and the world. Other than targeting the underlying cause, such as alcohol cessation and antiviral therapy, very few medical treatments can change the natural history of cirrhosis. Malnutrition is one of the few potentially modifiable factors that have been associated with cirrhosis severity and poor prognosis. The transition metal copper (Cu) is an essential trace metal that must be acquired from diet. Its metabolism is primarily regulated by the liver in its role as a master regulator of nutrients. In 2019, the investigators reported that Cu deficiency defined by below normal serum or liver concentrations occurred in a wide range of liver disorders and was associated with a severe disease phenotype. Improvement in liver function was observed in 2 of the 3 patients who received Cu supplementation. In 2023, the investigators conducted a longitudinal cohort study utilizing clinical, serum and liver explant tissue data from 183 cirrhosis patients. The investigators showed that Cu deficiency was associated with 2-fold higher infection rate and a more than 3-fold increase in the risk of death compared to patients with normal Cu status. These preliminary findings and the well-established importance of Cu in human health prompted the investigators to design the current pilot randomized, placebo-controlled, crossover trial to determine the effect of Cu supplementation on Cu dependent biochemical changes, patient safety and patient reported outcomes in cirrhosis.

The 2 groups in the trial

  • Copper supplementation 1st armTreatment being tested

    copper supplementation first, washout, then placebo

    Treatment: Copper Gluconate

  • Placebo first armTreatment being tested

    Placebo first, washout, then copper supplementation

    Treatment: Copper Gluconate

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Pilot Randomized Controlled Trial to Determine the Biochemical Effect, Safety and Patient Reported Outcomes of Copper Supplementation in Patients With Cirrhosis
Plain-language title
Copper supplements for adults with cirrhosis of the liverGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Record updated
13 March 2026